A metformin helye a 2-es típusú diabetesben szenvedok vércukorszint-csökkento terápiájában

Translated title of the contribution: The role of metformin in the glucose-lowering therapy of patients with type 2 diabetes

Research output: Contribution to journalArticle

Abstract

Metformin is the oral antidiabetic drug of choice for patients with type 2 diabetes. Its effect is predominantly based on the reduction of insulin resistance by inhibiting hepatic glucose production. Metformin can be used as an initial oral antidiabetic drug at the start of, or in case of the failure of lifestyle modifications. Metformin is also used in dual or triple oral antidiabetic combinations, however, its use should not be suspended even if initiation of insulin therapy is indicated in patients with type 2 diabetes. Metformin does not increase bodyweight and the risk of hypoglycaemia, and recent data suggest that it decreases the risk of tumour development. Today, an extended-release (XR) formulation is also available besides the traditional one, which not only simplifies the treatment, but might also reduce the incidence of gastrointestinal adverse effects.

Original languageHungarian
Pages (from-to)705-708
Number of pages4
JournalLege Artis Medicinae
Volume21
Issue number11
Publication statusPublished - Nov 2011

Fingerprint

Metformin
Type 2 Diabetes Mellitus
Hypoglycemic Agents
Glucose
Therapeutics
Hypoglycemia
Insulin Resistance
Life Style
Insulin
Liver
Incidence
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A metformin helye a 2-es típusú diabetesben szenvedok vércukorszint-csökkento terápiájában. / Jermendy, G.

In: Lege Artis Medicinae, Vol. 21, No. 11, 11.2011, p. 705-708.

Research output: Contribution to journalArticle

@article{dc596b7550404d8cba54f70a1a5d0117,
title = "A metformin helye a 2-es t{\'i}pus{\'u} diabetesben szenvedok v{\'e}rcukorszint-cs{\"o}kkento ter{\'a}pi{\'a}j{\'a}ban",
abstract = "Metformin is the oral antidiabetic drug of choice for patients with type 2 diabetes. Its effect is predominantly based on the reduction of insulin resistance by inhibiting hepatic glucose production. Metformin can be used as an initial oral antidiabetic drug at the start of, or in case of the failure of lifestyle modifications. Metformin is also used in dual or triple oral antidiabetic combinations, however, its use should not be suspended even if initiation of insulin therapy is indicated in patients with type 2 diabetes. Metformin does not increase bodyweight and the risk of hypoglycaemia, and recent data suggest that it decreases the risk of tumour development. Today, an extended-release (XR) formulation is also available besides the traditional one, which not only simplifies the treatment, but might also reduce the incidence of gastrointestinal adverse effects.",
keywords = "Biguanides, Metformin, Oral antidiabetic drugs, Type 2 diabetes",
author = "G. Jermendy",
year = "2011",
month = "11",
language = "Hungarian",
volume = "21",
pages = "705--708",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "11",

}

TY - JOUR

T1 - A metformin helye a 2-es típusú diabetesben szenvedok vércukorszint-csökkento terápiájában

AU - Jermendy, G.

PY - 2011/11

Y1 - 2011/11

N2 - Metformin is the oral antidiabetic drug of choice for patients with type 2 diabetes. Its effect is predominantly based on the reduction of insulin resistance by inhibiting hepatic glucose production. Metformin can be used as an initial oral antidiabetic drug at the start of, or in case of the failure of lifestyle modifications. Metformin is also used in dual or triple oral antidiabetic combinations, however, its use should not be suspended even if initiation of insulin therapy is indicated in patients with type 2 diabetes. Metformin does not increase bodyweight and the risk of hypoglycaemia, and recent data suggest that it decreases the risk of tumour development. Today, an extended-release (XR) formulation is also available besides the traditional one, which not only simplifies the treatment, but might also reduce the incidence of gastrointestinal adverse effects.

AB - Metformin is the oral antidiabetic drug of choice for patients with type 2 diabetes. Its effect is predominantly based on the reduction of insulin resistance by inhibiting hepatic glucose production. Metformin can be used as an initial oral antidiabetic drug at the start of, or in case of the failure of lifestyle modifications. Metformin is also used in dual or triple oral antidiabetic combinations, however, its use should not be suspended even if initiation of insulin therapy is indicated in patients with type 2 diabetes. Metformin does not increase bodyweight and the risk of hypoglycaemia, and recent data suggest that it decreases the risk of tumour development. Today, an extended-release (XR) formulation is also available besides the traditional one, which not only simplifies the treatment, but might also reduce the incidence of gastrointestinal adverse effects.

KW - Biguanides

KW - Metformin

KW - Oral antidiabetic drugs

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=83455177597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83455177597&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:83455177597

VL - 21

SP - 705

EP - 708

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 11

ER -